Mineralys Therapeutics Inc. Common Stock (MLYS)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Mineralys Therapeutics Inc. Common Stock, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Mineralys Therapeutics Inc. Common Stock (MLYS) has returned -25.35% so far this year and 70.59% over the past 12 months.

Based on dividend-adjusted daily data since Feb 10, 2023, MLYS's average daily return is +0.17%, while the average monthly return is +3.94%. At this rate, your investment would double in approximately 1.5 years.

Historically, 42% of months were positive and 58% were negative. The best month was Sep 2025 with a return of +145.0%, while the worst month was Sep 2023 at -25.9%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 5 months.

On a daily basis, MLYS closed higher 47% of trading days. The best single day was Sep 2, 2025 with a return of +86.4%, while the worst single day was Aug 14, 2024 at -22.8%.

Mineralys Therapeutics Inc. Common Stock has an annualized alpha of 31.39%, beta of 0.96, and R² of 0.03 versus S&P 500 Index. Calculated based on daily prices since February 13, 2023.

• This stock participated in 159.85% of S&P 500 Index downside but only 129.32% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.03 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

MLYS ranks 74 for risk / return — better than 74% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.

The table below present risk-adjusted performance metrics for Mineralys Therapeutics Inc. Common Stock (MLYS) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Mineralys Therapeutics Inc. Common Stock. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Mineralys Therapeutics Inc. Common Stock was 68.86%, occurring on Nov 22, 2023. Recovery took 443 trading sessions.

The current Mineralys Therapeutics Inc. Common Stock drawdown is 42.76%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Mineralys Therapeutics Inc. Common Stock over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Mineralys Therapeutics Inc. Common Stock is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.